Remarkable third quarter reported by Giovanni Carforio, BMS CEO

Giovanni Carforio, Bristol-Myers Squibb CEO, announced yesterday the results for Q3 2016, which exceed predictions by Wall Street analysts. Carforio attributed the positive results to the good performances by Opdivo—sales tripled—and Eliquis—sales doubled—which has made the shares rise by 3.8%. The company revenue grew to $4.9bn, corresponding to +21% vs Q3 2015. The company net earnings were $1.2bn, while analysts had predicted $1bn. BMS’ management took this opportunity to improve the current year forecast from EPS $2.4-$2.53 to $2.62-$2.72. (Source BMS)